Table 1 Baseline characteristics of patients with AS, PsA, uSpA and GP comparators at start of follow-up
AS (n = 6448) | PsA (n = 16,063) | uSpA (n = 5190) | GP (n = 266,435) | |
|---|---|---|---|---|
Sex | ||||
Males | 4390 (68.1) | 7217 (44.9) | 2325 (44.8) | 131,807 (49.5) |
Females | 2058 (31.9) | 8846 (55.1) | 2865 (55.2) | 134,628 (50.5) |
Age (years) | ||||
Mean (SD) | 50.0 (13.9) | 53.2 (13.8) | 44.7 (13.3) | 53.5 (15.9) |
18–29 years | 488 (7.6) | 761 (4.7) | 691 (13.3) | 18,465 (6.9) |
30–39 years | 1120 (17.4) | 2047 (12.7) | 1255 (24.2) | 36,805 (13.8) |
40–49 years | 1452 (22.5) | 3368 (21.0) | 1406 (27.1) | 52,122 (19.6) |
50–59 years | 1670 (25.9) | 4385 (27.3) | 1085 (20.9) | 63,559 (23.9) |
60–69 years | 1209 (18.8) | 3638 (22.6) | 583 (11.2) | 52,626 (19.8) |
70–79 years | 414 (6.4) | 1422 (8.9) | 132 (2.5) | 27,259 (10.2) |
≥ 80 years | 95 (1.5) | 442 (2.8) | 38 (0.7) | 15,599 (5.9) |
Start of follow-up | ||||
2006–2007 | 4938 (76.6) | 11,926 (74.2) | 3725 (71.8) | 266,234 (99.9) |
2008–2010 | 1510 (23.4) | 4137 (25.8) | 1465 (28.2) | 201 (0.1) |
Level of education | ||||
-≤9 years | 1423 (22.1) | 4039 (25.1) | 804 (15.5) | 68,776 (25.8) |
-10–12 years | 3096 (48.0) | 7983 (49.7) | 2566 (49.4) | 119,681 (44.9) |
->12 years | 1858 (28.8) | 3931 (24.5) | 1789 (34.5) | 74,587 (28.0) |
-Missing | 71 (1.1) | 110 (0.7) | 31 (0.6) | 3391 (1.3) |
SpA-related comorbiditiesa | ||||
Anterior uveitis | 1342 (20.8) | 252 (1.6) | 771 (14.9) | 1156 (0.4) |
Inflammatory bowel disease | 514 (8.0) | 346 (2.2) | 269 (5.2) | 2565 (1.0) |
Psoriasis | 145 (2.2) | 15,873 (98.8) | 162 (3.1) | 2190 (0.8) |
SpA-related medicationsb | ||||
Any DMARD | 1599 (24.8) | 6659 (41.5) | 1579 (30.4) | 2542 (1.0) |
-TNF inhibitors | 545 (8.5) | 758 (4.7) | 279 (5.4) | 268 (0.1) |
-Methotrexate | 494 (7.7) | 5094 (31.7) | 609 (11.7) | 1104 (0.4) |
-Sulfasalazin | 798 (12.4) | 1396 (8.7) | 877 (16.9) | 493 (0.2) |
NSAIDs | 3543 (54.9) | 7801 (48.6) | 2804 (54.0) | 28,467 (10.7) |
Prednisone | 659 (10.2) | 2133 (13.3) | 778 (15.0) | 4234 (1.6) |
Other comorbiditiesa | ||||
Ischemic heart disease | 468 (7.3) | 1091 (6.8) | 182 (3.5) | 14,849 (5.6) |
-ACS | 256 (4.0) | 576 (3.6) | 94 (1.8) | 8714 (3.3) |
Composite stroke | 201 (3.1) | 527 (3.3) | 84 (1.6) | 8954 (3.4) |
-Ischemic stroke | 92 (1.4) | 265 (1.6) | 49 (0.9) | 5009 (1.9) |
-Hemorrhagic stroke | 41 (0.6) | 100 (0.6) | 14 (0.3) | 1412 (0.5) |
-TIA | 77 (1.2) | 185 (1.2) | 28 (0.5) | 2951 (1.1) |
Venous thromboembolism | 115 (1.8) | 347 (2.2) | 80 (1.5) | 3835 (1.4) |
Diabetes | 311 (4.8) | 1025 (6.4) | 144 (2.8) | 10,118 (3.8) |
COPD | 122 (1.9) | 317 (2.0) | 48 (0.9) | 3507 (1.3) |
Atrial fibrillation or flutter | 264 (4.1) | 513 (3.2) | 87 (1.7) | 7430 (2.8) |
Other atherosclerotic disease | 210 (3.3) | 581 (3.6) | 101 (1.9) | 8318 (3.1) |
Dispensed prescriptionsb | ||||
Oral antidiabetics or insulin | 274 (4.2) | 1077 (6.7) | 123 (2.4) | 11,372 (4.3) |
Antihypertensive | 1794 (27.8) | 4853 (30.2) | 846 (16.3) | 59,053 (22.2) |
Statins | 657 (10.2) | 1871 (11.6) | 307 (5.9) | 23,180 (8.7) |
Aspirin | 557 (8.6) | 1519 (9.5) | 230 (4.4) | 23,655 (8.9) |
Warfarin | 174 (2.7) | 277 (1.7) | 52 (1.0) | 4328 (1.6) |